Back to results
US 7,071,310 B1Granted
Antibody against the human toll- like receptor 2 (tlr2) and uses thereof
AssigneeLeiv Eiriksson Nyskaping AS
InventorsTerje Espevik, Anders Sundan
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeLeiv Eiriksson Nyskaping AS
InventorsTerje Espevik, Anders Sundan
Estimating the term…
The present invention relates to an antibody capable of binding to human TLR2 and which (i) binds only to CD14+ cells in a normal human mononuclear cell population, and not to CD14− cells; (ii) does not inhibit LPS-induced activation of normal human mononuclear cells, and to the uses thereof, for example in the treatment of bacterial infections which are mediated via the TLR2 receptor, especially bacterial sepsis. In a particular embodiment of this aspects, a utility in the treatment of Listeria infections is proposed. The antibodies also have a utility as a general research tool, for example in screening for TLR2 expression, and in the study of TLR2 function. A further aspect of the invention provides use of an agent capable of inhibiting TLR2 activation in the preparation of a composition for the treatment of Listeria infections.
An isolated antibody that binds to human TLR2 and which
An isolated monoclonal antibody (designated as TL2.1) produced by the hybridoma cell line of European Collection of Cell Cultures (ECACC) deposit Accession No. 99102832.
An isolated antibody having the same binding specificities as antibody TL2.1 produced by the hybridoma of ECACC Accession No. 99102832.
A hybridoma or cell line being that on deposit at the ECACC under Accession No. 99102832, or producing an antibody having the binding specificities of monoclonal antibody TL2.1 produced by the hybridoma of ECACC accession No. 99102832.
A method of treatment of Listeria infection in a patient in need thereof, said method comprising administering to said patient an agent that inhibits TLR2 activation, wherein said agent is an anti-TLR2 antibody.
A method of inhibiting TLR2 activation in a patient in need of such inhibition, said method comprising administering to said patient an antibody that binds to human TLR2 and that (i) binds to CD14+ cells in a normal human mononuclear cell population, and not to CD14−;
Dependencies are inferred from the claim text.